Nasdaq's Biotech Competitors
Unless Europe can create viable public markets for companies likely to lose money for years, the European biotech industry will be dead before it gets to solve any of its other major problems (like finding capable managers or getting the buy-in of its best academics). So far most of the IPOs have not taken place where most of the start-ups are located--Germany. Still, the European markets do offer an intriguing alternative for US companies shut out of the US stock market.
You may also be interested in...
American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.